MetaCap

TELA Bio Inc. (TELA)

NASDAQ: TELAHealth CareMedical/Dental InstrumentsUSD

0.6885-0.0383 (-5.27%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

TELA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$31.11M
EPS (TTM)
-$0.74
52-week range
0.501 – 1.50
Day range
0.6721 – 0.8098
Volume / Avg
119.05K / 217.44K
Beta
—

52-week range

$0.501$1.50

TELA stock today

On Nov 20, TELA ended the session at $0.6885, shedding $0.0383 (5.27%), versus the S&P 500's 3.70% decline. At this level, TELA sits near the bottom of its 52-week range of $0.501 to $1.50: 54.1% below the high, set on Sep 23, 2026 and 37.4% above the low. TELA is down 41.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 41.2%.

TELA Bio has posted a net loss over the last twelve months (EPS of -$0.74), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About TELA Bio

Company profile

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene, polyglycolic acid, and polylactic-co-glycolic acid designed to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States.

Industry
Medical/Dental Instruments
CEO
Ms. Heather C. Getz CPA, M.B.A.
Headquarters
Malvern, PA
Employees
218
IPO year
2019

Financial highlights

Full financials

In fiscal 2025, TELA Bio generated $80.3 million in revenue, up 15.8% from fiscal 2024, its 8th consecutive year of revenue growth. TELA Bio reported a net loss of $38.8 million, compared with a loss of $37.8 million a year earlier. Gross margin was 67.7% (up from 67.1%) and operating margin -42.0%.

TELA Bio annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$80.28M$69.30M$58.45M$41.42M$29.46M
Growth+15.84%+18.56%+41.13%+40.58%+61.77%
Net income$-38.83M$-37.84M$-46.66M$-44.30M$-33.28M
EPS (diluted)$-0.83$-1.33$-2.04$-2.72$-2.30

Analyst forecast

Forecast

Consensus (6 analysts)

strong_buy

Avg. price target

$2.08+202.11%

  • Strong buy 1
  • Buy 4
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $1.00High $3.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$-0.16 vs $-0.19
Surprise
+15.79%

TELA news

All TELA news

TELA Bio peers

Health Care sector
TELA peer companies
CompanyPrice% ChgMarket capCompare
XTNTXtant Medical Holdings Inc.0.21-2.82%$29.49Mvs TELA
NSPRInspireMD Inc.0.54-12.97%$29.23Mvs TELA
MDAISpectral AI Inc. Class A1.04-20.61%$33.47Mvs TELA
NEPHNephros Inc.2.61-8.10%$28.37Mvs TELA
SRTSSensus Healthcare Inc.2.26-4.24%$37.20Mvs TELA
PLRZPolyrizon Ltd.9.31-8.42%$22.61Mvs TELA
DAVIDavion Healthcare Plc0.9001-9.99%$22.50Mvs TELA
DXRDaxor Corporation7.45-7.33%$43.49Mvs TELA

Indexes, lists and sector

TELA Bio stock FAQ

What is TELA Bio's stock price today?

TELA last traded at $0.6885 as of Nov 20, 4:00 PM EST, down 5.27% on the day. Prices are delayed at least 15 minutes.

Who is TELA Bio's CEO?

Ms. Heather C. Getz CPA, M.B.A. is the chief executive officer of TELA Bio Inc., which has about 218 employees.

What is the TELA 52-week high?

The 52-week high for TELA is $1.50 and the 52-week low is $0.501. The stock is currently 54.1% below its high.

Compare TELA